Protocol Details
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) and CLN3-Related Conditions
This study is currently recruiting participants.
Summary
Number | 18-CH-0002 |
Sponsoring Institute | National Institute of Child Health and Human Development (NICHD) |
Recruitment Detail | Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 1 wk
Max Age: 100 Years |
Referral Letter Required | No |
Population Exclusion(s) | Adults who are or may become unable to consent |
Keywords | Batten Disease;
Neurodegenerative;
Lysosomal Storage;
Biomarkers;
Longitudinal Study;
Natural History |
Recruitment Keyword(s) | None |
Condition(s) | Juvenile Neuronal Ceroid Lipofuscinosis (CLN3);
Batten Disease |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Institute of Child Health and Human Development |
Background:
CLN3, or Batten disease, is a genetic disorder. This deadly disease leads to decline of brain and nervous system functions. Symptoms of CLN3 typically occur between 4 and 7 years of age. They include changes in how a person sees, thinks, and moves. CLN3 can also cause seizures. No effective treatments for the disease are yet known. There is limited testing of potential therapies. Researchers want to study CLN3 more so they can improve future therapies.
Objective:
To identify clinical or biochemical markers that can be used as therapeutic outcome measures for CLN3.
Eligibility:
People with CLN3. It must be based on
Two CLN3 mutations OR
One CLN3 mutation AND findings seen with a powerful microscope
Family members of a person with CLN3.
Design:
Participants will have already been referred to NIH for CLN3 evaluation.
If participants agree to do the study, they will:
1) give spinal fluid, blood, urine, and skin samples. They may provide other samples if they were already collected. These may include cells, surgical specimens, and DNA.
2) will be seen by multiple healthcare specialists.
Participants may provide medical records or photos. Participants will sign a release of medical records form.P
Researchers may send samples or clinical data to other investigators. For research testing, the samples will not include the participant s name. For a test in a clinical lab, researchers will include the participant s name. These results will become part of the clinical record at NIH.
Eligibility
INCLUSION CRITERIA:
For the Main and Sub-Studies, participants > 1 week of age, of all genders, demographics, geographic locations, and disease severity will be recruited in order to obtain cross-sectional representation of CLN3-related conditions (Main and Sub-Studies) or all NCLs (Sub-Study B). Participants in the Main study will be followed at approximately yearly intervals to obtain longitudinal data. Participants in Sub-Study A may elect to send in medical records and samples only, or to come to the NIH for evaluations as outlined in Section 4. We anticipate that
participants in Sub-Study B will be seen mostly at NCL/CLN3-related family conferences.
Main Study:
Individuals > 1 week of age with a diagnosis of CLN3 or a CLN3-related/other NCL-type condition. Diagnosis determined by one of the following:
a. Two CLN3 or NCL condition-appropriate genetic mutations
b. One CLN3 mutation AND
i) clinical presentation suggestive of CLN3, OR
ii) characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits).
Sub-Study A:
Individuals > 1 week of age with a diagnosis of CLN3 or CLN3-related/other NCL-type condition. Diagnosis determined by one of the following:
a. Two CLN3 or condition-appropriate genetic mutations
b. One CLN3 mutation AND
i) clinical presentation suggestive of CLN3, OR
ii) characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits).
OR
Individuals > 1 month of age who have family member(s) diagnosed with CLN3 or CLN3-related/other NCL-type condition.
Sub-Study B:
Individuals > 1 week of age with a clinical diagnosis of CLN3 or NCL.
OR
Individuals > 1 month of age who have family member(s) diagnosed with CLN3 or NCL.
EXCLUSION CRITERIA:
Main Study:
1. Individuals who cannot travel to the NIH because of their medical condition.
2. Individuals who, in the opinion of the Investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation.
3.Females who are pregnant.
Sub-Studies A and B:
1. Unaffected individuals > 18 years of age who have cognitive impairments.
2. Individuals who, in the opinion of the Investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT03307304Protocol Details
Investigations of Juvenile Neuronal Ceroid Lipofuscinosis (CLN3) and CLN3-Related Conditions
This study is currently recruiting participants.
Summary
Number | 18-CH-0002 |
Sponsoring Institute | National Institute of Child Health and Human Development (NICHD) |
Recruitment Detail | Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 1 wk
Max Age: 100 Years |
Referral Letter Required | No |
Population Exclusion(s) | Adults who are or may become unable to consent |
Keywords | Batten Disease;
Neurodegenerative;
Lysosomal Storage;
Biomarkers;
Longitudinal Study;
Natural History |
Recruitment Keyword(s) | None |
Condition(s) | Juvenile Neuronal Ceroid Lipofuscinosis (CLN3);
Batten Disease |
Investigational Drug(s) | None |
Investigational Device(s) | None |
Intervention(s) | None |
Supporting Site | National Institute of Child Health and Human Development |
Background:
CLN3, or Batten disease, is a genetic disorder. This deadly disease leads to decline of brain and nervous system functions. Symptoms of CLN3 typically occur between 4 and 7 years of age. They include changes in how a person sees, thinks, and moves. CLN3 can also cause seizures. No effective treatments for the disease are yet known. There is limited testing of potential therapies. Researchers want to study CLN3 more so they can improve future therapies.
Objective:
To identify clinical or biochemical markers that can be used as therapeutic outcome measures for CLN3.
Eligibility:
People with CLN3. It must be based on
Two CLN3 mutations OR
One CLN3 mutation AND findings seen with a powerful microscope
Family members of a person with CLN3.
Design:
Participants will have already been referred to NIH for CLN3 evaluation.
If participants agree to do the study, they will:
1) give spinal fluid, blood, urine, and skin samples. They may provide other samples if they were already collected. These may include cells, surgical specimens, and DNA.
2) will be seen by multiple healthcare specialists.
Participants may provide medical records or photos. Participants will sign a release of medical records form.P
Researchers may send samples or clinical data to other investigators. For research testing, the samples will not include the participant s name. For a test in a clinical lab, researchers will include the participant s name. These results will become part of the clinical record at NIH.
Eligibility
INCLUSION CRITERIA:
For the Main and Sub-Studies, participants > 1 week of age, of all genders, demographics, geographic locations, and disease severity will be recruited in order to obtain cross-sectional representation of CLN3-related conditions (Main and Sub-Studies) or all NCLs (Sub-Study B). Participants in the Main study will be followed at approximately yearly intervals to obtain longitudinal data. Participants in Sub-Study A may elect to send in medical records and samples only, or to come to the NIH for evaluations as outlined in Section 4. We anticipate that
participants in Sub-Study B will be seen mostly at NCL/CLN3-related family conferences.
Main Study:
Individuals > 1 week of age with a diagnosis of CLN3 or a CLN3-related/other NCL-type condition. Diagnosis determined by one of the following:
a. Two CLN3 or NCL condition-appropriate genetic mutations
b. One CLN3 mutation AND
i) clinical presentation suggestive of CLN3, OR
ii) characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits).
Sub-Study A:
Individuals > 1 week of age with a diagnosis of CLN3 or CLN3-related/other NCL-type condition. Diagnosis determined by one of the following:
a. Two CLN3 or condition-appropriate genetic mutations
b. One CLN3 mutation AND
i) clinical presentation suggestive of CLN3, OR
ii) characteristic electron microscopy (EM) findings (such as curvilinear body, fingerprint profile, granular osmiophilic deposits).
OR
Individuals > 1 month of age who have family member(s) diagnosed with CLN3 or CLN3-related/other NCL-type condition.
Sub-Study B:
Individuals > 1 week of age with a clinical diagnosis of CLN3 or NCL.
OR
Individuals > 1 month of age who have family member(s) diagnosed with CLN3 or NCL.
EXCLUSION CRITERIA:
Main Study:
1. Individuals who cannot travel to the NIH because of their medical condition.
2. Individuals who, in the opinion of the Investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation.
3.Females who are pregnant.
Sub-Studies A and B:
1. Unaffected individuals > 18 years of age who have cognitive impairments.
2. Individuals who, in the opinion of the Investigator, are unable to comply with the protocol or have medical conditions that would potentially increase the risk of participation.
Citations:
Not Provided
Contacts:
Clinical Trials Number:
NCT03307304